Last reviewed 2026-04-23 · How we verify

TS-172

TS-172 is a small molecule that targets the serotonin receptor.

TS-172 is a small molecule that targets the serotonin receptor. Used for Treatment-resistant depression.

At a glance

Mechanism of action

TS-172 acts as a selective serotonin receptor antagonist, which is believed to contribute to its therapeutic effects. The exact mechanism of action is not fully understood, but it is thought to involve modulation of the serotonin system.

Approved indications

• Treatment-resistant depression

Common side effects

• Dizziness

Key clinical trials

• A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment (PHASE1)
• A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders (PHASE3)
• A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis (PHASE3)
• A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis (PHASE3)
• A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects (PHASE1)
• A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders (PHASE2)
• A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects (PHASE1)
• A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TS-172 CI brief — competitive landscape report
• TS-172 updates RSS · CI watch RSS
• Taisho Pharmaceutical Co., Ltd. portfolio CI